Innovating Translational Medicine: from the Laboratory to the Patient
The THE ecosystem adopts an integrated approach, “from laboratory to bedside and backward,” creating a virtuous cycle that begins with drug discovery and extends to clinical trials, continuously improving outcomes through a systematic methodology. We discuss this with Prof. Luisa Bracci, Full Professor of Biochemistry at the University of Siena and leader of THE’s Spoke 7.
Research Areas and Diseases Studied
-
Rare Diseases
-
In-depth study of diseases that, although considered “rare” individually, collectively affect a large number of patients.
-
Development of cross-cutting approaches and technologies applicable to various rare diseases.
-
-
Infectious Diseases and Antibiotic Resistance
-
Research on innovative drugs to combat antibiotic-resistant bacteria, a global challenge of enormous scale.
-
Development of a biomedical device to treat sepsis through a form of dialysis that removes harmful bacteria and cytokines.
-
-
Chronic Diseases and Aging
-
Approaches to counter arteriosclerosis and other aging-related diseases.
-
Research on bone regeneration, focusing on the Wnt molecular system to identify therapeutic targets and develop specific drugs.
-
The method of translational medicine and the integration of basic and clinical research are at the core of Spoke 7‘s activities. The goal is to translate scientific discoveries into effective treatments, improving patients’ quality of life and addressing public health challenges such as aging and antibiotic resistance.
